For press inquiries click here to contact us.
Xaira Therapeutics
2024 Nobel Prize in chemistry: Three scientists win for groundbreaking work in proteins
Alumis, Inc.
Promising Long-term Results for ESK-001 in Psoriasis
Xaira Therapeutics
LinkedIn Top Startups 2024: The 50 U.S. companies on the rise
Candid Therapeutics
With $370M debut, Candid Therapeutics is upfront about goal to lead a coming T-cell engager wave
Avenzo Therapeutics
Avenzo and Gilead partner for breast cancer combination regimen trial
Element Biosciences
Element Biosciences nets $277M ahead of new sequencer launch
Kinnate Biopharma
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
Xaira Therapeutics
Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D
Alumis, Inc.
Alumis closes $259M series C in year’s largest private biotech fundraise yet
Please see important disclaimers in the Terms section.